Leukemias, Chronic

(redirected from Chronic Leukemias)

Leukemias, Chronic

 

Definition

Chronic leukemia is a disease in which too many white blood cells are made in the bone marrow. Depending on the type of white blood cell that is involved, chronic leukemia can be classified as chronic lymphocytic leukemia or chronic myeloid leukemia.

Description

Chronic leukemia is a cancer that starts in the blood cells made in the bone marrow. The bone marrow is the spongy tissue found in the large bones of the body. The bone marrow makes precursor cells called "blasts" or "stem cells" that mature into different types of blood cells. Unlike acute leukemias, in which the process of maturation of the blast cells is interrupted, in chronic leukemias, the cells do mature and only a few remain as immature cells. However, even though the cells appear normal, they do not function as normal cells.
The different types of cells that are produced in the bone marrow are red blood cells (RBCs), which carry oxygen and other materials to all tissues of the body; white blood cells (WBCs), which fight infection; and platelets, which play a part in the clotting of the blood. The white blood cells can be further subdivided into three main types: the granulocytes, monocytes, and the lymphocytes.
The granulocytes, as their name suggests, have granules (particles) inside them. These granules contain special proteins (enzymes) and several other substances that can break down chemicals and destroy microorganisms such as bacteria.
Monocytes are the second type of white blood cell. They are also important in defending the body against pathogens.
The lymphocytes form the third type of white blood cell. There are two main types of lymphocytes: T lymphocytes and B lymphocytes. They have different functions within the immune system. The B cells protect the body by making "antibodies." Antibodies are proteins that can attach to the surfaces of bacteria and viruses. This attachment sends signals to many other cell types to come and destroy the antibody-coated organism. The T cell protects the body against viruses. When a virus enters a cell, it produces certain proteins that are projected onto the surface of the infected cell. The T cells can recognize these proteins and produce certain chemicals (cytokines) that are capable of destroying the virus-infected cells. In addition, the T cells can destroy some types of cancer cells.
Chronic leukemias develop very gradually. The abnormal lymphocytes multiply slowly, but in a poorly regulated manner. They live much longer and thus their numbers build up in the body. The two types of chronic leukemias can be easily distinguished under the microscope. Chronic lymphocytic leukemia (CLL) involves the T or B lymphocytes. B cell abnormalities are more common than T cell abnormalities. T cells are affected in only 5% of the patients. The T and B lymphocytes can be differentiated from the other types of white blood cells based on their size and by the absence of granules inside them. In chronic myelogenous leukemia (CML), the cells that are affected are the granulocytes.
Chronic lymphocytic leukemia (CLL) often has no symptoms at first and may remain undetected for a long time. Chronic myelogenous leukemia (CML), on the other hand, may progress to a more acute form.
Chronic leukemias account for 1.2% of all cancers. Because leukemia is the most common form of childhood cancer, it is often regarded as a disease of childhood. However, leukemias affect nine times as many adults as children. In chronic lymphoid leukemia, 90% of the cases are seen in people who are 50 years or older, with the average age at diagnosis being 65. The incidence of the disease increases with age. It is almost never seen in children. Chronic myeloid leukemias are generally seen in people in their mid-40s. It accounts for about 4% of childhood leukemia cases. According to the estimates of the American Cancer Society (ACS), approximately 29,000 new cases of leukemia will be diagnosed in 1998.

Causes and symptoms

Leukemia strikes both sexes and all ages. Although the cause is unknown, chronic leukemia is linked to genetic abnormalities and environmental factors. For example, exposure to ionizing radiation and to certain organic chemicals, such as benzene, is believed to increase the risks for getting leukemia. Chronic leukemia occurs in some people who are infected with two human retroviruses (HTLV-I and HTLV-II). An abnormal chromosome known as the Philadelphia chromosome is seen in 90% of those with CML. The incidence of chronic leukemia is slightly higher among men than women.
The symptoms of chronic leukemia are generally vague and non-specific. In chronic lymphoid leukemia (CLL), a patient may experience all or some of the following symptoms:
  • swollen lymph nodes
  • an enlarged spleen, which could make the patient complain of abdominal fullness
  • chronic fatigue
  • a general feeling of ill-health
  • fever of unknown origin
  • night sweats
  • weight loss that is not due to dieting or exercise
  • frequent bacterial or viral infections
In the early stages of chronic myeloid leukemia (CML), the symptoms are more or less similar to CLL. In the later stages of the disease, the patient may experience these symptoms:
  • non-specific bone pain
  • bleeding problems
  • mucus membrane irritation
  • frequent infections
  • a pale color due to a low red blood cell count (anemia)
  • swollen lymph glands
  • fever
  • night sweats

Diagnosis

There are no screening tests available for chronic leukemias. The detection of these diseases may occur by chance during a routine physical examination.
If the doctor has reason to suspect leukemia, he or she will conduct a very thorough physical examination to look for enlarged lymph nodes in the neck, underarm, and pelvic region. Swollen gums, an enlarged liver or spleen, bruises, or pinpoint red rashes all over the body are some of the signs of leukemia. Urine and blood tests may be ordered to check for microscopic amounts of blood in the urine and to obtain a complete differential blood count. This count will give the numbers and percentages of the different cells found in the blood. An abnormal blood test might suggest leukemia; however, the diagnosis has to be confirmed by more specific tests.
The doctor may perform a bone marrow biopsy to confirm the diagnosis of leukemia. During the bone marrow biopsy, a cylindrical piece of bone and marrow is removed. The tissue is generally taken out of the hipbone. These samples are sent to the laboratory for examination. In addition to diagnosis, bone marrow biopsy is also done during the treatment phase of the disease to see if the leukemia is responding to therapy.
Standard imaging tests such as x rays, computed tomography scans (CT scans), and magnetic resonance imaging (MRI) may be used to check whether the leukemic cells have invaded other organs of the body, such as the bones, chest, kidneys, abdomen, or brain.

Treatment

The treatment depends on the specific type of chronic leukemia and its stage. In general, chemotherapy is the standard approach to both CLL and CML. Radiation therapy is occasionally used. Because leukemia cells can spread to all the organs via the blood stream and the lymph vessels, surgery is not considered an option for treating leukemias.
Bone marrow transplantation (BMT) is becoming the treatment of choice for CML because it has the possibility of curing the illness. BMT is generally not considered an option in treating CLL because CLL primarily affects older people, who are not considered to be good candidates for the procedure.
In BMT, the patient's diseased bone marrow is replaced with healthy marrow. There are two ways of doing a bone marrow transplant. In an allogeneic bone marrow transplant, healthy marrow is taken from another person (donor) whose tissue is either the same or very closely resembles the patient's tissues. The donor may be a twin, a sibling, or a person who is not related at all. First, the patient's bone marrow is destroyed with very high doses of chemotherapy and radiation therapy. To replace the destroyed marrow, healthy marrow from the donor is given to the patient through a needle in the vein.
In the second type of bone marrow transplant, called an autologous bone marrow transplant, some of the patient's own marrow is taken out and treated with a combination of anticancer drugs to kill all the abnormal cells. This marrow is then frozen to save it. The marrow remaining in the patient's body is then destroyed with high dose chemotherapy and radiation therapy. Following that, the patient's own marrow that was frozen is thawed and given back to the patient through a needle in the vein. This mode of bone marrow transplant is currently being investigated in clinical trials.
In chronic lymphoid leukemia (CLL), chemotherapy is generally the treatment of choice. Depending on the stage of the disease, single or multiple drugs may be given. Drugs commonly prescribed include steroids, chlorambucil, fludarabine, and cladribine. Low dose radiation therapy may be given to the whole body, or it may be used to alleviate the symptoms and discomfort due to an enlarged spleen and lymph nodes. The spleen may be removed in a procedure called a splenectomy.
In chronic myeloid leukemia (CML), the treatment of choice is bone marrow transplantation. During the slow progress (chronic phase) of the disease, chemotherapy may be given to try to improve the cell counts. Radiation therapy, which involves the use of x rays or other high-energy rays to kill cancer cells and shrink tumors, may be used in some cases to reduce the discomfort and pain due to an enlarged spleen. For chronic leukemias, the source of radiation is usually outside the body (external radiation therapy). If the leukemic cells have spread to the brain, radiation therapy can be directed at the brain. As the disease progresses, the spleen may be removed in an attempt to try to control the pain and to improve the blood counts.
In the acute phase of CML, aggressive chemotherapy is given. Combination chemotherapy, in which multiple drugs are used, is more efficient than using a single drug for the treatment. The drugs may either be administered intravenously through a vein in the arm or by mouth in the form of pills. If the cancer cells have invaded the central nervous system (CNS), chemotherapeutic drugs may be put into the fluid that surrounds the brain through a needle in the brain or back. This is known as intrathecal chemotherapy.
Biological therapy or immunotherapy is a mode of treatment in which the body's own immune system is harnessed to fight the cancer. Substances that are routinely made by the immune system (such as growth factors, hormones, and disease-fighting proteins) are either synthetically made in a laboratory, or their effectiveness is boosted and they are then put back into the patient's body. This treatment mode is also being investigated in clinical trials all over the country at major cancer centers.

Prognosis

The prognosis for leukemia depends on the patient's age and general health. According to statistics, in chronic lymphoid leukemia, the overall survival for all stages of the disease is nine years. Most of the deaths in people with CLL are due to infections or other illnesses that occur as a result of the leukemia.
In CML, if bone marrow transplantation is performed within one to three years of diagnosis, 50-60% of the patients survive three years or more. If the disease progresses to the acute phase, the prognosis is poor. Less than 20% of these patients go into remission.

Key terms

Antibodies — Proteins made by the B lymphocytes in response to the presence of infectious agents, such as bacteria or viruses, in the body.
Biopsy — The surgical removal and microscopic examination of living tissue for diagnostic purposes.
Chemotherapy — Treatment with drugs that act against cancer.
Computerized tomography (CT) scan — A series of x rays put together by a computer in order to form detailed pictures of areas inside the body.
Cytokines — Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors."
Immunotherapy — Treatment of cancer by stimulating the body's immune defense system.
Lumbar puncture — A procedure in which the doctor inserts a small needle into the spinal cavity in the lower back to withdraw some spinal fluid for testing. Also known as a "spinal tap."
Magnetic resonance imaging (MRI) — A medical procedure using a magnet linked to a computer to picture areas inside the body.
Maturation — The process by which stem cells transform from immature cells without a specific function into a particular type of blood cell with defined functions.
Radiation therapy — Treatment using high-energy radiation from x-ray machines, cobalt, radium, or other sources.
Remission — A disappearance of a disease as a result of treatment. Complete remission means that all disease is gone. Partial remission means that the disease is significantly improved by treatment, but residual traces of the disease are still present.

Prevention

Most cancers can be prevented by changes in lifestyle or diet, which will reduce the risk factors. However, in leukemias, there are no known risk factors. Therefore, at the present time, there is no way known to prevent the leukemias from developing. People who are at an increased risk for developing leukemia because of proven exposure to ionizing radiation, the organic liquid benzene, or people who have a history of other cancers of the lymphoid system (Hodgkin's lymphoma) should undergo periodic medical checkups.

Resources

Organizations

American Cancer Society. 1599 Clifton Rd., NE, Atlanta, GA 30329-4251. (800) 227-2345. http://www.cancer.org.
Cancer Research Institute. 681 Fifth Ave., New York, N.Y. 10022. (800) 992-2623. http://www.cancerresearch.org.
Leukemia Society of America, Inc. 600 Third Ave., New York, NY 10016. (800) 955 4572. http://www.leukemia.org.
National Cancer Institute. Building 31, Room 10A31, 31 Center Drive, MSC 2580, Bethesda, MD 20892-2580. (800) 422-6237. http://www.nci.nih.gov.
Oncolink. University of Pennsylvania Cancer Center. http://cancer.med.upenn.edu.
References in periodicals archive ?
This document, which builds on CLSI document Enumeration of Immunologically Defined Cell Populations by Flow Cytometry (H42), covers issues specific to the study of samples of acute and chronic leukemias, non-Hodgkin's lymphomas, plasma cell neoplasms, and myelodysplastic syndromes.
Coverage will encompass the application of oncogenes, genomics (gene expression profiles, microRNAs), proteomics growth factors, cell markers, cell cycle and differentiation agents, novel therapeutics and clinical trials in both the acute and chronic leukemias as well as the myelodysplastic syndromes.
Aberrant expressions of CD antigens have been found mainly in acute but also in chronic leukemias.
Chronic leukemias are a complex group of blood disorders that can be quite insidious in their appearance.
Based on these results, we are moving ahead with new clinical studies of Evoltra([R]) in other disease areas, such as MDS, chronic leukemias and solid tumors.
Our study provides clear evidence that cancer cells in women with acute and chronic leukemias can contaminate the ovaries," said Marie-Madeleine Dolmans, MD, professor at the Universite Catholique de Louvain in Brussels and lead author of the study.
com/reports/c28243) has announced the addition of Chronic Leukemias - Curative Intent Raises the Bar to their offering.
OTCBB: BIOV) today commented on interim results of a Phase II study of its lead compound, clofarabine, for the treatment of pediatric acute and chronic leukemias.
This is an important distinction from acute leukemia and accounts for the less severe early course of chronic leukemias.
TRISENOX is also being evaluated in an ambitious development program in more than 40 clinical and investigator-sponsored trials in front-line APL and other malignancies including multiple myeloma, myelodysplastic syndrome, non-Hodgkin's lymphoma, hormone refractory prostate cancer, melanoma, glioblastoma, and acute and chronic leukemias.
TRISENOX is currently being studied in more than 40 clinical and investigator-sponsored trials and CTI anticipates having more than 60 trials ongoing later this year focusing on the efficacy of TRISENOX in multiple myeloma, myelodysplastic syndrome, non-Hodgkin's lymphoma, hormone refractory prostate cancer, melanoma, glioblastoma, and acute and chronic leukemias.
Genasense is being broadly tested in more than 20 randomized and non- randomized trials for its ability to increase the effectiveness of current types of anticancer therapy for a number of diseases, including acute and chronic leukemias, multiple myeloma, non-Hodgkin's lymphoma, and cancers of the breast, colon, kidney, lung, liver, pancreas, and prostate.